FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Canada. That letter and what it means was the focus of a recent InvestmentPitch Media video. In the video, InvestmentPitch Media’s Cassandra Bolinski discusses the company’s recent receipt of the letter, which provides regulatory approval for FSD Pharms to move forward with its phase 1 clinical trial of LUCID-21-302 or Lucid-MS. A novel drug candidate for the treatment of multiple sclerosis (“MS”), Lucid-MS has shown ability to prevent myelin degradation (demyelination), a known cause of MS and other neurogenerative diseases. The substance appears to be nonimmunomodulatory, which is important distinction in the potential for developing new options for treating MS. InvestmentPitch Media specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound FSD201, a proprietary ultramicronized palmitoyl ethylamine (“PEA”) for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of its lead compounds: Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company.